GLUE Company Profile and Key Details

GLUE has shown sold momentum, gaining 3.04% over the past week and 143.18% over the past quarter, though year-to-date performance is up 55.87%. Short-term trend indicators are mixed aligned (SMA20 -4.22%, SMA50 -6.02%, SMA200 73.03%). The stock’s 14-day RSI is 43.66 (neutral), while the ATR of 1.3 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -28.21% below its high and over 428.56% above its low. Average 10-day trading volume of 821.12 thousand shares is below the 3-month average of 1.12 million, indicating normal recent market interest.

Monte Rosa Therapeutics, Inc. generated EPS of $0.31 over the past year. Five-year average earnings growth is -41.09%. Wall Street analysts project EPS growth of -17.25% annually over the next five years. The latest quarter delivered EPS of -$0.33. The next quarter is forecast at -$0.34. Next year's EPS is expected at -$13.82. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 2 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $37.00 to $13.00. The high target offers 87.06% upside. The low target suggests -34.28% downside. The mean target is $27.86. This offers 40.85% upside. Monte Rosa Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 06, 2025, missed forecasts by -15.38%. The prior quarter beat by -51.61%. Over the last six quarters, Apple has recorded several small beats. These include -99.91% in August 08, 2024.

Monte Rosa Therapeutics, Inc. has 61.76 million shares outstanding. The public float is 30.30 million shares, elevated short interest at 18.68% of float. This equals 8.70 million shares. The short ratio is 20.0 days. Institutional investors hold 101.16% of the float. Insiders own 0.73%. Mathers Edward T holds 7.69 million shares, Sonsini Peter W. has 7.69 million shares and SANDELL SCOTT D has 7.69 million shares. Over the past six months, insider transactions show net selling. They sold 77.92 thousand shares across 14 transactions.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) closed at $19.98 USD, gaining $0.20 (1.01%) from the previous close of $19.78. The stock is currently mid-range between its 52-week high and low $3.51 and $25.77. With a market capitalization of about $1.30 billion, Monte Rosa Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.64). Key stats such as the average daily volume over the past year has been around 1.12 million shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Monte Rosa Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Markus Warmuth, the company employs approximately 142 people and listed since June 24, 2021. Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.

Monte Rosa Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $19.50. This means the shares are trading near this model’s fair value.

Monte Rosa Therapeutics, Inc. trades at a P/E ratio of -33.56, slightly below the S&P 500 average, with a price-to-sales ratio of 10.42 and a price-to-book ratio of 5.56 trading at moderately above to book value. The P/FCF stands at -46.84, also below market averages.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) shares are up 55.87% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Monte Rosa Therapeutics, Inc. trading at a premium to the broader market with a P/E of -33.56. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $19.62, suggesting -0.81% downside. Our AI forecast model points to short-term strength (5.61% over two weeks), a medium-term rise (8.44% over three months), and a longer-term gain (10.57% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Monte Rosa Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.61%, with price expected at $20.89 by May 01, 2026, within a range of $20.30 to $21.50 3-Month Outlook: Projected rise of 8.44%, reaching $21.45 by July 16, 2026, with a range of $21.02 to $21.92. 1-Year Outlook: Projected gain of 10.57%, with price at $21.87 by April 16, 2027, within a range of $20.28 to $23.19.